SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Posted inDiabetes & Endocrinology Neurology news

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective confirmation.
SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort
Posted inDiabetes & Endocrinology news Rheumatology

SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential immunomodulatory benefits of SGLT-2 inhibitors beyond glycemic control.
Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
Posted inDiabetes & Endocrinology Gastroenterology news

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver health, glycemic control, and lipid profiles, underscoring potential dietary strategies for MASLD management.
Long-term Stroke Risk in Chinese Adults with Newly Diagnosed Diabetes and Impaired Glucose Tolerance: Insights from the 34-Year Da Qing Diabetes Study
Posted inClinical Updates Diabetes & Endocrinology Neurology news Specialties

Long-term Stroke Risk in Chinese Adults with Newly Diagnosed Diabetes and Impaired Glucose Tolerance: Insights from the 34-Year Da Qing Diabetes Study

A 34-year follow-up of the Da Qing Diabetes Study reveals significantly increased stroke incidence among Chinese adults with newly diagnosed type 2 diabetes and impaired glucose tolerance, highlighting the beneficial impact of lifestyle intervention, particularly in women.
Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately controlled by dual therapy.